News
Weight-loss drug craze boosts $80 billion Lilly Endowment to largest in U.S.
The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the founding family's endowment become the largest private foundation in the U.S. At the end of 2024, the Lilly Endowment had $79.9 billion in assets, according to filings released May 16.
3don MSN
Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...
Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...
The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...
Viking Therapeutics has key trial catalysts ahead and trades near biotech deal valuations, despite dilution risks. Find out ...
The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the ...
Pharma giant Eli Lilly’s weight loss drug Mounjaro is priced between Rs. 10,000- ₹15,000 in India making it inaccessible to a ...
6don MSN
Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback